Macquarie University, Sydney Macquarie University ResearchOnline

Showing items 1 - 12 of 12.

Add to Quick Collection   All 12 Results

  • First
  • Previous
  • 1
  • Next
  • Last
Sort:
 Add All Items to Quick Collection
Date: 2016
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1116179
Description: 4 page(s)
Reviewed: Reviewed
Date: 2016
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1116428
Description: Purpose: Tumor-derived circulating cell–free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAF ... More
Reviewed: Reviewed
Date: 2016
Subject Keyword: BRAF | dabrafenib | MEK | melanoma | pyrexia | trametinib
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1196003
Description: BRAF mutations occur commonly in metastatic melanomas and inhibition of mutant BRAF and the downstream kinase MEK results in rapid tumor regression and prolonged survival in patients. Combined therapy ... More
Reviewed: Reviewed
Date: 2015
Language: eng
Resource Type: conference paper
Identifier: http://hdl.handle.net/1959.14/1108520
Description: Background: Acquired resistance (AR) to BRAF inhibitors (BRAFi) in melanoma is a near-universal phenomenon driven by numerous genetic and non-genetic alterations. Clinical implications of these AR mec ... More
Reviewed: Reviewed
Date: 2015
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1059667
Description: Background: BRAF inhibitors (BRAFi) cause paradoxical activation of the MAPK pathway in keratinocytes resulting in cutaneous squamous cell carcinoma (cuSCC). Objective: We sought to examine the clinic ... More
Reviewed: Reviewed
Date: 2014
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/1110040
Description: Background: The MEK inhibitor trametinib is currently undergoing clinical trials as the treatment of metastatic melanoma both alone and in combination with the BRAF inhibitor dabrafenib. One of the mo ... More
Reviewed: Reviewed
Date: 2014
Language: eng
Resource Type: conference paper abstract
Identifier: http://hdl.handle.net/1959.14/1107074
Description: Background: MEK1 mutations can confer resistance to BRAF inhibitors although pre-existing MEK1P¹²⁴ mutations do not preclude clinical responses to BRAF inhibitor therapy. We sought to determine if pre ... More
Reviewed: Reviewed
Date: 2014
Subject Keyword: BRAF | ipilimumab | melanoma | sequencing | vemurafenib
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/340824
Description: Background: The immunotherapy (IT) agents ipilimumab and interleukin-2 as well as BRAF inhibitors (BRAFi) vemurafenib and dabrafenib, with or without trametinib (MEK inhibitors), are all FDA-approved ... More
Reviewed: Reviewed
Date: 2014
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/340689
Description: Background: Recent phase 3 trials have shown an overall survival benefit in metastatic melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded as a reliable surrogate fo ... More
Reviewed: Reviewed
Date: 2013
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/294005
Description: Purpose BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this study was to determine the response rate (RR) for the selective, allost ... More
Reviewed: Reviewed
Date: 2013
Language: eng
Resource Type: journal article
Identifier: http://hdl.handle.net/1959.14/294292
Description: Purpose: Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently showed improved progression-free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. T ... More
Reviewed: Reviewed
  • First
  • Previous
  • 1
  • Next
  • Last